Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus sintilimab for advanced colorectal cancer
ChiCTR2200064904Phase 4Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib and sintilimab in colorectal cancer (CRC), sponsored by Anqing Municipal Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
surufatinibsintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200064904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064904.